Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.

Gordon EM, Sankhala KK, Chawla N, Chawla SP.

Adv Ther. 2016 Jul;33(7):1055-71. doi: 10.1007/s12325-016-0344-3. Epub 2016 May 27. Review.

2.

Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.

Villar VH, Vögler O, Barceló F, Martín-Broto J, Martínez-Serra J, Ruiz-Gutiérrez V, Alemany R.

PLoS One. 2016 May 24;11(5):e0155946. doi: 10.1371/journal.pone.0155946. eCollection 2016.

3.

The value of trabectedin in the treatment of soft tissue sarcoma.

Nakamura T, Matsumine A, Sudo A.

Ther Clin Risk Manag. 2016 Jan 13;12:73-9. doi: 10.2147/TCRM.S84789. eCollection 2016. Review.

4.

Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).

Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J; Spanish Group for Research on Sarcoma.

Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46. doi: 10.1007/s00280-015-2809-5. Epub 2015 Nov 12.

5.

Primary pulmonary synovial sarcoma: a case report with unique and impressive computed tomography findings.

Kambo JS, Richardson B, Ionescu DN, Tucker T, Kraushaar G.

Can Respir J. 2015 Jan-Feb;22(1):e1-3.

6.

Radiation-induced leiomyosarcoma of the prostate after brachytherapy for prostatic adenocarcinoma.

Horiguchi H, Takada K, Kamihara Y, Ibata S, Iyama S, Sato T, Hayashi T, Miyanishi K, Sato Y, Takimoto R, Kobune M, Kobayashi K, Hirayama Y, Masumori N, Hasegawa T, Kato J.

Case Rep Oncol. 2014 Aug 16;7(2):565-70. doi: 10.1159/000366294. eCollection 2014 May.

7.

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.

Ueda T, Kakunaga S, Ando M, Yonemori K, Sugiura H, Yamada K, Kawai A.

Invest New Drugs. 2014 Aug;32(4):691-9. doi: 10.1007/s10637-014-0094-5. Epub 2014 Apr 3.

8.

Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network.

Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, Dhanda R, Nadler E.

Sarcoma. 2014;2014:145764. doi: 10.1155/2014/145764. Epub 2014 Jan 12.

9.

Targeted therapy for sarcomas.

Forscher C, Mita M, Figlin R.

Biologics. 2014 Mar 17;8:91-105. doi: 10.2147/BTT.S26555. eCollection 2014. Review.

10.
11.

Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results.

Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE.

Cancers (Basel). 2013 May 10;5(2):529-49. doi: 10.3390/cancers5020529.

12.

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group.

Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, Ray-Coquard I, Chabaud S, Penel N, Berge Y, Dômont J, Italiano A, Duffaud F, Cadore AC, Polivka V, Blay JY.

Br J Cancer. 2013 Aug 20;109(4):909-14. doi: 10.1038/bjc.2013.442. Epub 2013 Aug 6.

13.

Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.

Hoiczyk M, Grabellus F, Podleska L, Ahrens M, Schwindenhammer B, Taeger G, Pöttgen C, Schuler M, Bauer S.

Int J Oncol. 2013 Jul;43(1):23-8. doi: 10.3892/ijo.2013.1928. Epub 2013 May 2.

14.

Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom.

Guest JF, Sladkevicius E, Gough N, Linch M, Grimer R.

Sarcoma. 2013;2013:863056. doi: 10.1155/2013/863056. Epub 2013 Mar 17.

15.

New drugs and combinations for the treatment of soft-tissue sarcoma: a review.

Somaiah N, von Mehren M.

Cancer Manag Res. 2012;4:397-411. doi: 10.2147/CMAR.S23257. Epub 2012 Nov 23.

16.

Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.

Keedy VL.

Onco Targets Ther. 2012;5:153-60. doi: 10.2147/OTT.S19055. Epub 2012 Aug 22.

17.

Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.

Villar VH, Vögler O, Martínez-Serra J, Ramos R, Calabuig-Fariñas S, Gutiérrez A, Barceló F, Martín-Broto J, Alemany R.

PLoS One. 2012;7(5):e37735. doi: 10.1371/journal.pone.0037735. Epub 2012 May 25.

18.

MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.

Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S.

Mol Cancer Ther. 2012 Jan;11(1):174-82. doi: 10.1158/1535-7163.MCT-11-0529. Epub 2011 Nov 14.

19.

Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Riedel RF.

Cancer. 2012 Mar 15;118(6):1474-85. doi: 10.1002/cncr.26415. Epub 2011 Aug 11. Review.

20.

Role of trabectedin in the treatment of soft tissue sarcoma.

Christinat A, Leyvraz S.

Onco Targets Ther. 2009 Feb 18;2:105-13.

Items per page

Supplemental Content

Write to the Help Desk